Overhauling Compliance and GMPs

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-04-02-2003, Volume 27, Issue 4

FDA's newly launched risk-based approach to GMP regulation spurs signficant changes in the agency's approach to inspection processes, postapproval changes, and 21 CFR Part 11 enforcement.

Related Content:

Regulatory/GMP ComplianceQuality SystemsRegulatory WatchPharmaceutical Technology-04-02-2003
Using Continuous Processes and Automation to Remove Contamination Risk
Takeda Receives Japanese Regulatory Approval for HYQVIA Subcutaneous Injection for Treating Agammaglobulinemia or Hypogammaglobulinemia
FDA Releases Draft Guidance on Sampling and Testing of In-Process Materials and Drug Products